TCGA-B6-A0RH-01A-21R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 215
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- PANCREAS_BETA_CELLS+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- COAGULATION+0.300
- CHOLESTEROL_HOMEOSTASIS+0.290
- MYOGENESIS+0.280
- GLYCOLYSIS+0.260
- HYPOXIA+0.260
Top 10 suppressed
- MITOTIC_SPINDLE-0.450
- WNT_BETA_CATENIN_SIGNALING-0.320
- PROTEIN_SECRETION-0.310
- G2M_CHECKPOINT-0.260
- TGF_BETA_SIGNALING-0.250
- UV_RESPONSE_DN-0.200
- NOTCH_SIGNALING-0.190
- E2F_TARGETS-0.130
- ANDROGEN_RESPONSE-0.120
- HEME_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.838 |
| 2 | TCGA-C8-A12Y-01A-11R-A12D-07 | — | B | 0.832 |
| 3 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.789 |
| 4 | TCGA-A7-A56D-01A-11R-A27Q-07 | — | B | 0.766 |
| 5 | MDT-AP-2585 | Med | Medulloblastoma | 0.746 |
| 6 | TCGA-XF-A9SJ-01A-11R-A39I-07 | — | — | 0.736 |
| 7 | MDT-AP-2299 | Med | Medulloblastoma | 0.728 |
| 8 | 9c8140ab-454c-4f62-aa6e-d1cfe4e498e0 | — | — | 0.723 |
| 9 | TCGA-E2-A9RU-01A-11R-A41B-07 | — | B | 0.717 |
| 10 | 8da8aaa5-5059-4c87-a32b-8c99ebeeb52d | — | — | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |